tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Difei Yang, 209 are a BUY (90.87%), 19 are a HOLD (8.26%), 2 are a SELL (0.87%).
Analyst Difei Yang, carries an average stock price target met ratio of 53.8% that have a potential upside of 49.72% achieved within 456 days. Previously, Difei Yang worked at MIZUHO, AEGIS, BREAN.
Difei Yang’s has documented 469 price targets and ratings displayed on 38 stocks. The coverage was on Healthcare, Industrials sectors.
Most recent stock forecast was given on MGTA, Magenta Therapeutics at 18-Apr-2022.
Analyst best performing recommendations are on RLYP (RELYPSA).
The best stock recommendation documented was for RLYP (RELYPSA) at 7/18/2016. The price target of $26 was fulfilled within 3 days with a profit of $5.75 (28.4%) receiving and performance score of 94.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Dec-2019
$13
3 years 11 months 3 days ago
(29-Aug-2022)
1/6 (16.67%)
$4.7 (56.63%)
176
Buy Since 07-Nov-2019
$20
3 years 11 months 8 days ago
(24-Aug-2022)
0/5 (0%)
$14.21 (245.42%)
Buy Since 09-Jan-2020
$29
3 years 11 months 8 days ago
(24-Aug-2022)
0/2 (0%)
$14.55 (100.69%)
Hold Since 23-Aug-2022
$15.25
$27
3 years 11 months 9 days ago
(23-Aug-2022)
9/13 (69.23%)
$0.09 (0.59%)
174
Buy Since 17-Sep-2015
$14
3 years 11 months 9 days ago
(23-Aug-2022)
7/19 (36.84%)
$7.75 (124.00%)
211
What Year was the first public recommendation made by Difei Yang?
